INHIBITORS OF THE CHEMOKINE RECEPTOR CxCR3
    4.
    发明申请
    INHIBITORS OF THE CHEMOKINE RECEPTOR CxCR3 有权
    化疗受体CxCR3的抑制剂

    公开(公告)号:US20100305088A1

    公开(公告)日:2010-12-02

    申请号:US12852076

    申请日:2010-08-06

    CPC分类号: C07D295/033 C07D471/20

    摘要: This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.

    摘要翻译: 本发明涉及如本文所定义的3-(酰氨基或磺酰氨基)-4-(4-取代 - 哒嗪基)苯甲酰胺或苯磺酰胺化合物。 3-(酰氨基或磺酰氨基) - (4-取代 - 吖嗪基)苯甲酰胺或苯磺酰胺化合物可用作趋化因子受体CxCR3的抑制剂,并且用于预防或治疗CxCR3趋化因子受体介导的疾病或与患者相关的病症 需要这样的。

    Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
    9.
    发明授权
    Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals 有权
    三氮杂和四氮杂蒽醌二酮衍生物,其制备及其作为药物的用途

    公开(公告)号:US07132536B2

    公开(公告)日:2006-11-07

    申请号:US10829064

    申请日:2004-04-21

    IPC分类号: C07D471/14

    CPC分类号: C07D471/14 C07D487/04

    摘要: The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, wherein A, B and R1 to R5 are as defined herein. The compounds of formula I are valuable pharmacologically active compounds. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译: 本发明涉及式I的三氮杂和四氮杂蒽并二酮衍生物,其中A,B和R 1至R 5如本文所定义。 式I的化合物是有价值的药理活性化合物。 它们可用于治疗各种疾病状态,包括心血管疾病如动脉粥样硬化,血栓形成,冠状动脉疾病,高血压和心功能不全。 它们上调酶内皮一氧化氮(NO)合酶的表达,并且可以在需要所述酶的增加的表达或增加的NO水平或降低的NO水平的归一化的条件下应用。 本发明还涉及式I化合物的制备方法,其用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。

    Preparative separation of mixtures by mass spectrometry
    10.
    发明授权
    Preparative separation of mixtures by mass spectrometry 失效
    通过质谱法制备混合物分离

    公开(公告)号:US06750448B2

    公开(公告)日:2004-06-15

    申请号:US10386127

    申请日:2003-03-10

    IPC分类号: H01J4930

    CPC分类号: H01J49/0086

    摘要: The present invention provides an instrument and methods for the preparative separation of components of mixtures using mass spectrometric methods. Nondestructive ionization methods are employed to generate ionized components of a mixture, the ionized components are spatially separated by mass and the mass-separated ion components are trapped. The ion source and mass spectrometric techniques employed allow the generation of large ion currents of ion components, on the order of nanoamps, which facilitate rapid accumulation of nanomole quantities of mass-separated components in relatively short times (minutes to hours).

    摘要翻译: 本发明提供了使用质谱法制备分离混合物组分的仪器和方法。 采用非破坏性电离方法产生混合物的离子化成分,离子化成分在空间上被质量分离,质量分离的离子成分被捕获。 使用的离子源和质谱技术允许产生大约数量级的离子组分的大离子电流,这有助于在相当短的时间(几分钟至几小时)内快速积累纳摩尔量的质量分离组分。